InventisBio Co., Ltd. is a startup based in China, most recent round Series-c-plus, 2 tracked investors.
InventisBio Co., Ltd. is a startup founded in 2021 based in China. Its most recent tracked round is Series-c-plus. Brouky records 2 investors associated with the company.
InventisBio is a clinical-stage biotechnology company headquartered in Shanghai, China, developing small-molecule drugs for oncology, autoimmune diseases and metabolic disorders. The company has two approved drugs and multiple clinical candidates, including TYK2 inhibitor D-2570 and oral SERD taragarestrant (D-0502), with core programs advancing through Phase III registration trials.
Funding rounds, investor list, risk signals, and comparable startups, all gated to subscribers.